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http://www.biomedcentral.com/1472-6963/13/225RESEARCH ARTICLE Open AccessA review of decision support, risk communication
and patient information tools for thrombolytic
treatment in acute stroke: lessons for tool
developers
Darren Flynn1*, Gary A Ford2, Lynne Stobbart1, Helen Rodgers2, Madeleine J Murtagh3 and Richard G Thomson1Abstract
Background: Tools to support clinical or patient decision-making in the treatment/management of a health
condition are used in a range of clinical settings for numerous preference-sensitive healthcare decisions. Their
impact in clinical practice is largely dependent on their quality across a range of domains. We critically analysed
currently available tools to support decision making or patient understanding in the treatment of acute ischaemic
stroke with intravenous thrombolysis, as an exemplar to provide clinicians/researchers with practical guidance on
development, evaluation and implementation of such tools for other preference-sensitive treatment options/
decisions in different clinical contexts.
Methods: Tools were identified from bibliographic databases, Internet searches and a survey of UK and North
American stroke networks. Two reviewers critically analysed tools to establish: information on benefits/risks of
thrombolysis included in tools, and the methods used to convey probabilistic information (verbal descriptors,
numerical and graphical); adherence to guidance on presenting outcome probabilities (IPDASi probabilities items)
and information content (Picker Institute Checklist); readability (Fog Index); and the extent that tools had
comprehensive development processes.
Results: Nine tools of 26 identified included information on a full range of benefits/risks of thrombolysis. Verbal
descriptors, frequencies and percentages were used to convey probabilistic information in 20, 19 and 18 tools
respectively, whilst nine used graphical methods. Shortcomings in presentation of outcome probabilities (e.g.
omitting outcomes without treatment) were identified. Patient information tools had an aggregate median Fog
index score of 10. None of the tools had comprehensive development processes.
Conclusions: Tools to support decision making or patient understanding in the treatment of acute stroke with
thrombolysis have been sub-optimally developed. Development of tools should utilise mixed methods and
strategies to meaningfully involve clinicians, patients and their relatives in an iterative design process; include
evidence-based methods to augment interpretability of textual and probabilistic information (e.g. graphical displays
showing natural frequencies) on the full range of outcome states associated with available options; and address
patients with different levels of health literacy. Implementation of tools will be enhanced when mechanisms are in
place to periodically assess the relevance of tools and where necessary, update the mode of delivery, form and
information content.
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Clinicians and patients are frequently faced with making
a decision about medical or surgical treatment when
there are multiple reasonable options (including where
appropriate the option of doing nothing) with different
balances of short- and long-term benefits, risks and result-
ant consequences, which are sensitive to individual patient
preferences and values [1-3]. Examples of these types of
preference-sensitive healthcare decisions/options include
treatment of early-stage prostate cancer; screening for
genetic conditions; diagnostic tests for suspected gastro-
intestinal disorders; and medical treatment options for
secondary prevention of cardiovascular disease. In con-
trast to decisions about preference-sensitive care, effective
care refers to decisions about treatments that are consid-
ered to be a ‘standard’ course of action with largely un-
equivocal evidence of highly favourable benefit-to-harm
ratios, and where consideration of patient/carer prefer-
ences and values would add minimal or no value, as there
is clearly one superior treatment option [1] For example,
repair of fractures and significant lacerations are consid-
ered standard [effective] care.
In contrast to decisions about effective care, evidence-
based tools such as clinical decision support tools [4],
patient decision aids [5], patient information leaflets [6]
and risk communication tools [7] are warranted to help
clinicians weigh-up the pros and cons of available ‘prefer-
ence-sensitive’ options by presenting them with evidence-
based summaries of the likely magnitude of benefit to risk
ratios. Such tools also warranted to (i) promote patient
understanding of the available options and probabilistic
information on the different balances of benefits, risks and
consequences to support choice; and (ii) support clinicians
in communicating the latter information to patients, in
order to facilitate the process of informed consent, includ-
ing engagement of patients in shared decision making
with clinicians [1]. Tools such as structured patient deci-
sion aids, designed specifically to engage patients in shared
decision making, impact positively on patients’ knowledge
of available options, perception of risk, decisional conflict,
clarity about their preferences on available options,
patient-practitioner communication and patient involve-
ment in decision making, including reductions in unwar-
ranted variation in rates of preference-sensitive treatment
and care [5].
Tools to support clinical and patient decision-making
or patient understanding in the treatment/management
of a health condition are used in a range of clinical
settings for a myriad of preference-sensitive healthcare
decisions, although their impact in clinical practice is
largely dependent on their quality across a range of
domains. Tools should be underpinned by a systematic
development process, with reference to evidence-based
methods, in order to establish the optimal mode ofdelivery (electronic or paper-based); form (e.g., graphical
methods to convey probabilistic information on outcome
states associated with the options); and information
content (e.g., comprehensiveness of information on the
health condition of interest and available options for
treatment, derived from best evidence, including strat-
egies to support health literacy such as readability of
textual information and interpretability of probabilistic
information by both clinicians and patients) [6,8-13].
The decision to treat or not treat acute ischaemic
stroke with intravenous thrombolysis (recombinant tissue
plasminogen activator, rt-PA) is a further example of a
preference-sensitive healthcare decision, which presents
unique challenges for development of tools to support
patient understanding / decision making about treat-
ment. Benefit from thrombolysis is time dependent and
treatment must be administered within a maximal time
window of 4.5 hours from onset of symptoms [14,15].
However, thrombolysis has adverse effects, the most
serious being bleeding complications that can cause
symptomatic intracranial haemorrhage (SICH) within
24–36 hours following treatment, which usually leads to
severe disability or death [16,17], although overall
mortality with thrombolysis is not increased and risk of
long-term disability significantly reduced [18,19].
Given the extreme time dependent context and the
gravity of the potential risks from thrombolysis, clini-
cians as well as patients (or their relatives/proxy in situa-
tions where a patient lacks capacity) are faced with
making rapid decisions about treatment that involve de-
liberation of trade-offs between the increased likelihood
of long-term benefit from thrombolysis (reduced risk of
significant post-stroke disability) and the more immedi-
ate bleeding risks and consequences [20,21]. Health
(outcome) states following stroke are sensitive to patient
values [22]; however acute stroke is often experienced by
patients and relatives as a shocking and traumatic event,
which can encumber their understanding of verbal infor-
mation conveyed by clinicians [23].
Despite evidence of effectiveness, thrombolytic treat-
ment rates for acute stroke are below optimal levels [24].
Other than eligible patients presenting too late to second-
ary care [25] and limited infrastructure to deliver thromb-
olysis [26], factors associated with clinical decisions not to
offer thrombolytic treatment to patients/relatives include
physicians’ uncertainty about administering thrombolysis
[27]; physicians' concern about risk of SICH [28]; lack of
consensus on relative contraindications [29]; and a lack of
data to allow decisions to be supported by differential ef-
fectiveness based on individual patient characteristics [30].
A variety of tools may help: to support decision mak-
ing about thrombolysis; clinicians to convey accurate
information on benefits, risks and likely consequences
of treating acute ischaemic stroke, with and without
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informed consent; and (where appropriate) engagement
of patients/relatives in shared decision making within
the emergency (hyperacute) period of stroke.
We critically analysed currently available tools to
support decision making or patient understanding in
the treatment of acute ischaemic stroke with intraven-
ous thrombolysis, in order to provide clinicians and
researchers with practical guidance on development,
evaluation and implementation of such tools for other
preference-sensitive treatment options/decisions in
different clinical contexts.
Methods
We included currently available paper-based or electronic
tools to support decision making, patient understanding
and risk communication in acute thrombolytic treatment.
Eligible tools had to fulfil the following criteria: focus ex-
clusively on intravenously-administered thrombolysis for
treatment of acute ischaemic stroke; include textual or nu-
merical information on risks and benefits of thrombolysis;
and written in the English language. Tools were excluded
if they focused on arterial thrombolysis or entry in clinical
trials.
Included tools were categorised as:
 Brief decision aids: designed to guide clinical
decision making about thrombolysis, and/or engage
patients/relatives in decision making by facilitating
understanding of the available options and
concomitant risks/benefits.
 Risk communication tools: primarily focused on
communication of probabilistic information to
patients/relatives on risks/benefits of thrombolysis.
 Patient information tools: primarily designed for
patients/relatives to facilitate understanding of
diagnosis, treatment, and management, but not
specifically to engage them in decision making [5].
 Standardised information for clinicians: primarily
designed to support clinicians in explaining the
risks/benefits of thrombolysis to patients/relatives.
Search strategy
Searches (covering the period 1995 to 16th August 2011)
were conducted across five bibliographic databases
(Medline, EMBASE, PsycINFO, CINAHL and Scopus)
using a combination of keywords and MeSH headings.
An example of the search strategy can be found in
Additional file 1. We also searched the bibliographies
of included studies and conducted citation searching
using ISI Web of Knowledge.
Key representatives of national stroke networks (UK,
North America and Australia) were contacted to dissem-
inate a request to identify tools used nationally or locallyto support decision making and risk communication in
acute thrombolytic treatment. An Internet search using
Google™ was also conducted.
Tools identified were independently screened for eligi-
bility by two reviewers (DF, RGT). Disagreements were
resolved through discussion.
Data extraction and critical analysis
An iterative process, involving pilot testing and discus-
sions between two reviewers (RGT, DF), was used to
develop a structured data extraction form.
Data extraction was undertaken independently by both
reviewers and disagreements resolved through discus-
sion. The data extraction form captured: title, author(s),
country of origin, publication/review date, type of tool
(e.g., brief decision aid), format (paper, website, elec-
tronic); length (number of A4 pages); and citations in
tools to primary or secondary research evidence.
Data were also extracted on: (i) numerical data or a
description of acute stroke outcomes included in tools
in terms of death; extent of disability (with reference to a
widely-used outcome measure in acute stroke care - the
modified Rankin Scale [31]); risk of SICH; and impact of
SICH following thrombolysis; (ii) methods used to convey
probabilistic information on acute stroke outcomes
(textual [e.g. verbal descriptors such as ‘higher chance’],
numerical [percentages, number needed to treat/harm
or frequencies] or graphical risk presentations [e.g.,
pictograph]), including the use of colour in graphical
risk presentations, and red-green colour blind friendli-
ness (absence of concurrent use of red and green); and
(iv) adherence to good practice on presentation of out-
come probabilities assessed with an 8-item 'probabil-
ities' checklist from the International Patient Decision
Aid Standards Instrument (IPADSi) [12]. The IPDASi
probabilities checklist has four response options, al-
though during pilot testing difficulties were encoun-
tered with grading responses from strongly agree to
strongly disagree; consequently response options for the
IPDASi probabilities checklist were collapsed into
‘agree’ and ‘disagree’ (coded as 1 and 0 respectively;
minimum/maximum score 0 and 8). Comprehensiveness
of the development process was assessed with a 6-item
checklist based on the Medical Research Council Frame-
work for Design and Evaluation of Complex Interventions
[9] and on relevant items from IPDASi [12].
Patient information tools were assessed for: (i) read-
ability using the Fog Index [32] - total number of years
in education needed to understand the text: 0.4 × (mean
sentence length [number of words divided by the number
of sentences] + percentage of hard words) - calculated
using an online tool [33]; and (ii) information content
(clarity of aims, provision of accurate/unbiased informa-
tion, facilitating decision making, conflicts of interest,
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checklist developed by the Picker Institute [6]. This check-
list utilised a 5-point scale ranging from no (score of 1) to
yes (score of 5) – for this review these 28 items were
coded as ‘agree’ or ‘disagree’ (coded as 1 and 0 respect-
ively; minimum/maximum score 0 and 28).
Based on independent assessment by both reviewers,
percentage (raw) agreement between raters was calcu-
lated for items in the IPDASi (probabilities), information
content and development process checklists. Percentage
agreement on the IPDASi (probabilities) items (except
for the item on use of natural frequencies [63%]) and de-
velopment process checklists indicated good/substantial
agreement between raters (78% to 100%). Except for
items relating to descriptions of the condition (67%) and
authors’/developers’ credentials or qualifications (56%),
there was a good level of agreement between raters on
the information content (Picker Institute) checklist (72%
to 100%).
Results
Twenty six tools were identified (Figure 1). Fourteen
originated from the UK, nine from the USA, and three
from Canada (Table 1). Seventeen were patient informa-
tion tools [34-50]; five risk communication tools [51-55];
three brief decision aids [56-58]; and one standardised
information for clinicians [59]. Patient information and
risk communication tools were paper-based (n = 18) or1,823 records identified through 
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Figure 1 Flowchart summary of the process used to identify tools.web pages (n = 4). Fifteen of these were equivalent in
length to one or two pages of A4; the remainder were
equivalent to three or four (n = 4), six or eight (n = 2) or
ten pages of A4 (n = 1). All three brief decision aids were
electronic tools that used predictive equations to calculate
outcomes for individual patients.
Acute stroke outcomes included in tools
Tools that included a description or numerical data on
benefits (functional independence), adverse outcomes
(dependency or dependency and death combined), death,
intracranial haemorrhage (ICH) and the impact of ICH
following treatment with thrombolysis are shown in
Table 2. Information on independence was included in
25 out of 26 tools. Only 14 out of 26 tools (five out of
five risk communication tools, six out of 17 patient
information tools, two out of three brief decision aids
and the single standardised information for clinicians)
included information on dependency (or dependency
combined with death). Information on death was in-
cluded in only 10 out of 26 tools (four out of five risk
communication tools, five out of 17 patient information
tools and in the standardised information for clinicians).
Information on intracranial haemorrhage (ICH) was
included in 25 out of 26 tools, with 20 describing the
impact of ICH.
Five patient information tools [34,38,41,45,48], three risk
communication tools [51-53] and the single standardised27 tools identified through other 
sources
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s/other sources 
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d in narrative 
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Table 1 Summary of tools included in the review
Title Organization/Authors Country Publication date
(review date)
Type of Tool
(research evidence)
Format / Length
HandiStroke: A handheld tool for the
emergent evaluation of acute stroke
patients
Shapiro et al. USA 2003 (NS) Brief decision aid (NINDS) Electronic/palm-based
The stroke-thrombolytic predictive
instrument
Kent et al. USA 2006 (NS) Brief decision aid (NINDS
1&2, ATLANTIS A&B,
ECASS II)
Electronic/web-based
tool
Patient Information Leaflet:
Thrombolysis (treatment with a clot
dissolving drug - alteplase) for acute
stroke
The University of North
Staffordshire NHS Trust
UK 2007 (NS) Patient information tool
(NICE)
Paper/1 x A4
After a stroke starts: What you need
to know about clot-busting therapy
Genentech USA 2007 (NS) Patient information tool
(NINDS)
Paper/10 x A4
tPA for stroke: potential benefit, risk
and alternatives
American Academy of
Emergency Medicine
USA 2007 (NS) Risk communication tool
(NINDS, ECASS I/II,
ATLANTIS, MAST-I/E, ASK,
Cochrane Review and
other literature)
Paper/3 x A4
Clot-busting treatment for acute stroke:
patient information
NHS Lothian UK 2007 (NS) Risk communication tool
(Research evidence NS)
Paper/1 x A4
Clot-busting treatment for acute stroke:
patient information
NHS Lothian UK 2008 (NS) Risk communication tool
Research evidence NS
Paper/1 x A4
Information for Patients about
thrombolysis (clot dissolving drugs) for
stroke
Royal United Hospital
Bath NHS Trust
UK 2008 (Sep 2011) Patient information tool
(Research evidence NS)
Paper/2 x A4
Tissue Plasminogen Activator (tPA)
what you should know
American College of
Emergency Physicians,
American Academy of
Neurology, American Heart
Association/American
Stroke Association
USA 2008 (NS) Patient information tool
(FDA)
Paper/1 x A4
Thrombolytic Treatment of Acute
Ischaemic Stroke
Patient UK UK 2008 (Nov 2011) Patient information tool
(MAST-I/E, ASK, NINDS,
ECASS I/II, ATLANTIS, STAT,
SITS-MOST, NICE)
Web page/6 x A4
The Outcome Wheel a potential tool
for shared decision-making in ischemic
stroke thrombolysis
Cunningham Canada 2008 (NS) Brief decision aid (NINDS) Electronic/Excel file
Information to give to patients/relatives
before administration of Alteplase
Stroke Northumbria UK 2009 (NS) Standardised Information
(Research evidence NS)
Paper/< 1 A4
Stroke Thrombolysis (Clot Dissolving
Drugs): an information leaflet
Stockport NHS Foundation
Trust
UK 2009 (Mar 2010) Patient information tool
(Research evidence NS)
Paper/3 x A4
Information for Patients and families
about tPA (Tissue Plasminogen) for
Stroke
The Ottawa Hospital Canada 2009 (NS) Patient information tool
(Research evidence NS)
Paper/1 x A4
Acute Stroke Thrombolysis University Hospitals Bristol
NHS Foundation Trust
UK 2009 (NS) Patient information tool
(Research evidence NS)
Paper/4 x A5
Thrombolysis Treatment after Stroke Chest, Heart and Stroke
Scotland
UK 2009 (NS) Patient information tool
(Research evidence NS)
Paper/16 x A5
Hypothetical representation of 16
patients treated with Activase (t-PA)
vs 16 patients treated with placebo is
based on NINDS results at 3 months
Genentech USA 2009 (NS) Risk communication tool
(NINDS 2)
Web page/3 x A4
Alteplase: a treatment for stroke:
Information for patients
Knapp et al. UK 2010 (NS) Patient information tool
(NINDS, ECASS, SITS-MOST)
Paper/4 x A5
Assessment and improvement of
figures to visually convey benefit and
risk of stroke thrombolysis
Gadhia et al. USA 2010 (NS) Risk communication tool
(NINDS)
Paper/1 xA4
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Table 1 Summary of tools included in the review (Continued)
Patient and carer information leaflet:
thrombolysis in stroke
NHS Wales UK 2010 (expires 2013) Patient information tool
(NICE/SITS-MOST)
Paper/4 x A4
t-PA information sheet Saint Alphonsus Health
System Outreach Program
USA 2010 (NS) Patient information tool
(FDA)
Paper/1 x A4
Patient Information Sheet for
Thrombolysis
NHS Fife UK 2010 (NS) Patient information tool
(Research evidence NS)
Paper/1 x A4
Stroke Thrombolysis Information for
Patients and Relatives
Gloucestershire Hospitals
NHS Foundation Trust
UK 2011 (NS) Patient information tool
(Research evidence NS)
Web page/2 x A4
Stroke Thrombolysis - Information
Sheet
South Tyneside NHS
Foundation Trust
UK 2011 (NS) Patient information tool
(Research evidence NS)
Paper/2 x A4
Patient Information Sheet Massachusetts General
Hospital Stroke Service
USA Unknown (NS) Patient information tool
(FDA)
Paper/1 x A4
Information about tPA Thunder Bay Regional
Health Sciences Centre
Canada Unknown (NS) Patient information tool
(Research evidence NS)
Web page/1 x A4
NS = not stated.
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both the potential benefits (independence) and the entire
range of adverse outcomes following thrombolysis (de-
pendency, death [or dependency combined with death],
ICH, and the impact of ICH).
Methods used to convey probabilistic information
Numerical methods (percentages, frequencies [e.g., “30
out of 100” or “1 in 3 treated patients” have a good out-
come] or number needed to treat/harm) used to convey
probabilistic information on outcomes are shown in
Table 3. Verbal descriptors, frequencies and percentages
were used in 20, 19 and 18 tools respectively. A minority
(five out of 17) of patient information tools used number
needed to treat/harm. Verbal descriptors were a princi-
pal feature of patient information tools (16 out of 17),
along with frequencies (13 out of 17). Frequencies (five
out of five) and percentages (four out of five) were domin-
ant characteristics of risk communication tools. Brief deci-
sion aids only included percentages. The standardised
information for use by clinicians utilised verbal descriptors
and frequencies.Table 2 Acute stroke outcomes included in tools
Patient information tool
(n = 17)
Risk communi
(n = 5)
Good outcome* 17 (100) 5 (100) | |
Poor outcome** 2 (12) 5 (100) | |
Poor outcome/death*** 4 (24) 1 (20) | |
Death 5 (29) 4 (80)
Intra-cranial hemorrhage (ICH) 17 (100) 5 (100) | |
Outcome following ICH 16 (94) 3 (60) | |
Figures are frequencies (percentage frequencies).
* functional independence (no symptoms to slight disability) – approximating to m
** dependence (moderate to severe disability) - approximating to modified Rankin
*** dependence combined with death.
| | one risk communication tool displayed these outcomes using only graphical metNine tools used graphical methods. Graphical methods
were used in all five risk communication tools [51-55],
but infrequently in patient information tools (three out
of 17 [34,39,44]) and brief decision aids (one out of three
[58]). Colour was a feature in seven graphical risk pre-
sentations, but three [34,51,52] could potentially cause
perceptual difficulties for people with red-green colour-
blindness.
Readability and information content of patient
information tools
Patient information tools were likely to be comprehen-
sible to most patients/relatives with an aggregate median
Fog index equivalent to 10 years of education required
to understand the text (Table 4). Only six out of 17 patient
information tools fulfilled ≥50% of the (total score ≥15 out
of 28) Picker Institute criteria [34-36,39,41,46]. Short-
comings were notable in categories relating to conveying
accurate information and facilitating decision making,
including items on descriptions of the condition, nat-
ural course of acute stroke without treatment and ac-
knowledging uncertainty.cation tool Brief decision aid
(n = 3)
Standardised information
(n = 1)
Overall
(n = 26)
2 (67) 1 (100) 25 (96)
0 (0) 1 (100) 8 (31)
2 (67) 0 (0) 7 (27)
0 (0) 1 (100) 10 (39)
2 (67) 1 (100) 25 (96)
0 (0) 1 (100) 20 (77)
odified Rankin Scale [31] 0 to 1, or 0 to 2.
Scale 3 to 5.
hods.
Table 3 Methods used to present probabilistic information
Textual Numerical Graphical
Verbal descriptors Percentages Number needed to
treat/harm
Frequencies Pie chart Bar graph Pictogram/graph
Patient Information Tool 16 (94) 11 (65) 5 (29) 13 (77) 0 (0) 2 (12) 1 (6)
Risk Communication Tool 3 (60) 4 (80) 0 (0) 5 (100)* 1 (20) 0 (0) 4 (80)
Brief Decision Aid 0 (0) 3 (100) 0 (0) 0 (0) 1 (33) 0 (0) 0 (0)
Standardised Information 1 (100) 0 (0) 0 (0) 1 (100) 0 (0) 0 (0) 0 (0)
Overall 20 (77) 18 (69) 5 (19) 19 (73) 2 (8) 2 (8) 5 (19)
Figures are frequencies (percentage frequencies).
* one risk communication tool showed frequencies graphically.
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process
Risk communication tools attracted the highest median
IPDASi (probabilities) total scores (Table 5), with two ful-
filling seven or all eight criteria [51,53]. One patient infor-
mation tool fulfilled seven criteria [34]. Six was the highest
total assigned to a brief decision aid [58]. Most tools in-
cluded probabilities for treatment options (25 out of 26),
specified the reference group (25 out of 26) and presented
outcomes using frequencies (19 out of 26). Conversely,
relatively few included specific time horizons for outcome
probabilities (ten out of 26); outcome probabilities for
treatment with and without thrombolysis using identical
denominators and time horizons (seven out of 26); ac-
knowledgement of uncertainty (three out of 26); multiple
methods of viewing probabilities (11 out of 26); or satisfac-
torily addressed framing bias (eight out of 26).
None of the tools fulfilled all six development process
criteria (Table 5). Sources of evidence were explicitly cited
in 14 out of 26 tools, primarily from randomised con-
trolled trials of thrombolysis (Table 1). Three presented
evidence of development informed by established theory
or body of evidence [34,52,58]. Usability testing and in-
volvement of steering groups in development was evident
for only three [34,41,52] and four [35,36,41,52] tools re-
spectively. None of the tools identified provided evidence
that studies had been undertaken to elicit the information
needs of users (clinicians, patients or their relatives), or
that the tools had been tested in an exploratory trial.
Discussion
We critically analysed 26 tools that aimed to support de-
cision making or patient understanding in the treatment
of acute stroke with thrombolysis, and the majority dem-
onstrated considerable deficiencies. Only nine tools in-
cluded information on a full range of both benefits and
risks of treatment with thrombolysis. The great majority
of tools used frequencies to convey probabilistic infor-
mation on acute stroke outcomes. However, a majority
of tools also used verbal descriptors and percentages,
which can cause difficulties with understanding andinterpretation [60,61]. Furthermore, many tools only
presented frequencies for a good outcome, and used verbal
descriptors or percentages to convey information on ad-
verse outcomes. Whilst the great majority of tools specified
the patient group to which the outcome probabilities ap-
plied, they did not compare outcomes with and without
thrombolysis, did not use identical denominators and time
horizons, and failed to adhere to other good practice
guidance on presentation of outcome probabilities. Out-
come probabilities were also frequently underpinned by
aggregate-level evidence (where stated) on the benefit to
harm ratios derived from randomised controlled trials,
which may not necessarily reflect outcomes for individual
patients within routine practice [62]. Graphical methods
were used infrequently to convey probabilistic information,
despite evidence that they can enhance risk perception by
exploiting rapid (automatic) perceptual capabilities of users
[63]. Patient information tools would be understood by the
majority of patients/relatives; but not those with low health
literacy. It is recommended that health information mate-
rials should be written at no higher than 5th to 6th grade
reading levels [64,65], in order to maximise universal un-
derstanding in the adult population [equating to Fog Index
scores of < 7]. Deficiencies in information content of pa-
tient information tools were also identified. The great ma-
jority of tools lacked development informed by theory or
involvement of clinicians, patients and relatives, and were
not pilot tested in actual acute stroke settings.
Our findings are not unique to tools designed to sup-
port decision-making and patient understanding in the
treatment acute stroke with thrombolysis. They reflect
those of previous studies in other clinical settings/domains
that have identified deficiencies in information content,
methods of conveying probabilistic information, and lack
of comprehensive development processes [6,66-70].
Strengths and limitations
The strengths of this review include a comprehensive
search strategy and critical appraisal of tools across mul-
tiple relevant domains. The authors also have experience
of developing and evaluating tools to support decision
Table 4 Information content [6] and readability assessment of patient information tools (n = 17)
Start with a clear statement of aims? N %
Describes its purpose (e.g. to aid decision-making) 9 53
Describes what it covers (to help the reader judge whether it’s worth carrying on) 8 47
Describes who it is for (i.e. which patient groups) 15 88
Provide unbiased and detailed information about options?
Describes the health condition 8 47
Describes the natural course without treatment 7 41
Lists the treatment/management/lifestyle options 9 53
Describes benefits of options 17 100
Describes risks of options (harms/side-effects/disadvantages) 17 100
Describes uncertainty around the current evidence (i.e. what is not known) 1 6
Describes procedures (i.e., treatments, targets, monitoring, behaviour change, etc.) 15 88
Contain accurate information?
Clearly states the evidence sources used in compiling the information 8 47
Information quoted is in line with the most up-to-date clinical evidence 8 47
Where mentioned, prevalence estimates give an accurate impression of how common/rare the condition is 1 6
Personal opinion and/or advertising are clearly distinguished from evidence-based information 5 29
Help patients to make appropriate decisions
Acknowledges (explicitly or implicitly) that the patient has decisions to make 8 47
Helps patients to imagine what it is like to live with the condition and/or treatment effects 4 24
Asks patients to consider factors (e.g. priorities, motivations, treatment outcomes) affecting possible courses of action 2 12
Suggests ways and/or provides tools to help patients make decisions 1 6
Disclose conflicts of interest?
Includes authors’ / developers’ credentials or qualifications 9 53
Reports source of funding for development and distribution 6 35
Have a clear structure and layout?
Is consistent in design and layout throughout 17 100
Includes aids to finding information (e.g. contents, index, site map, or search facility) 5 29
Important points are emphasised through the use of summaries and/or bullet points 10 59
Illustrates information with diagrams and/or pictures 7 41
Where diagrams appear, they are labelled and relate to the subject matter 5 29
Sections are clearly separated 14 82
Help the reader judge its reliability
Reports date of publication 10 59
Includes sources of further information 7 41
Information content total: median (IQR), min/max 13 (6.5), 5/23
Readability (Fog Index): median (IQR), min/max 10.0 (2.9), 7.5/15.9
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thus adding further context expertise to the review. In
terms of weaknesses, we may have missed tools that are
unpublished or unavailable via the Internet, although we
also surveyed key clinical networks. We may have also
missed unpublished information on development pro-
cesses for tools.
Implications for research
Our findings have implications that go beyond tools for
this clinical setting to other contexts where decisionsupport and risk presentation is being developed. In
order to address the shortcomings of tools identified
in this review, including analogous tools to support
patient understanding and decision making about other
preference-sensitive medical or surgical treatment options,
tool development should adhere to a structured develop-
ment process, recommendations of previous research
[66-69] and published guidance [6,10-13] in order to:
(i) identify the views and perspectives of clinicians and pa-
tients/relatives about treatment decision-making about the
available options (for example, in-depth interviews or focus
Table 5 IPDASi (probabilities) and development process ratings for tools
IPDASi (Probabilities) items [12] Development process items
1 n
(%)
2 n
(%)
3 n
(%)
4 n
(%)
5 n
(%)
6 n
(%)
7 n
(%)
8 n
(%)
Median (IQR)
probabilities
total
1 n
(%)
2 n
(%)
3 n
(%)
4 n
(%)
5 n
(%)
6n
(%)
RCT 5 (100) 5 (100) 5 (100) 2 (40) 2 (40) 1 (20) 4 (80) 5 (100) 5 (3) 3 (60) 1 (20) 0 (0) 1 (20) 1(20) 0 (0)
PIT 17 (100) 17 (100) 13 (77) 6 (36) 2 (12) 1 (6) 6 (36) 3 (18) 4 (1.5) 8 (47) 1 (6) 0 (0) 2 (12) 3 (18) 0 (0)
BDA 2 (67) 2 (67) 0 (0) 2 (67) 2 (67) 1 (33) 1 (33) 0 (0) 4 (0) 3 (100) 1 (33) 0 (0) 0 (0) 0 (0) 0 (0)
SI 1 (100) 1 (100) 1 (100) 0 (0) 1 (100) 0 (0) 0 (0) 0 (0) 4 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Overall 25 (96) 25 (96) 19 (73) 10 (39) 7 (27) 3 (12) 11 (42) 8 (31) 4 (2) 14 (54) 3 (12) 0 (0) 3 (12) 4 (15) 0 (0)
RCT = Risk communication tool PIT = Patient information tool BDA = Brief decision aid SI = Standardised information.
IPDASi (Probabilities) items: [12].
1 = provides information about outcome probabilities (OPs) associated with the options; 2 = specifies defined group (reference class) of patients for which the OPs
apply; 3 = specifies the event rates for OPs (in natural frequencies); 4 = specifies time period over which the OPs apply; 5 = allows the user to compare OPs across
options using the same denominator and time period; 6 = provides information about the levels of uncertainty around event/OPs; 7 = provides more than one
way of viewing the probabilities; 8 = provides balanced information about event or OPs to limit framing biases.
Development process items:
1 = evidence that developers have considered best available evidence; 2 = intervention based on an established theory/body of evidence; 3 = elicitation study on
risk/benefit information required by patients/families or clinicians; 4 = tool subjected to ‘testing’ in patients and families or clinicians; 5 = development of tool
guided by steering group; 5 = tool subjected to exploratory trial.
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ical setting which may shape decision-making about the
available options (for example ethnographic methods); and
(iii) understand how tools work in practice (usability test-
ing of alpha prototypes outwith the target clinical setting,
and subsequent feasibility testing in the actual clinical
setting), and therefore how they may be improved/adapted
to the specific context of the clinical setting.
Patient decision aids utilising a structured development
process have been described previously; for example to
support decision-making about stroke prevention in atrial
fibrillation [71]; management of chest pain in the emer-
gency department [72]; and surgical options for breast
cancer [73].
Development of tools should utilise mixed methods
and appropriate strategies to meaningfully involve clini-
cians, patients and their relatives in an iterative design
process to establish the optimal mode, form and content
of tools in the specific context of the clinical setting.
Evidence-based methods should also be utilised to
augment interpretability of probabilistic information. In
particular, presenting a balanced synopsis of the benefits/
risks of treatment with and without the available options
(and absolute difference in terms of likely benefit or harm)
using natural frequencies [61,74,75] with identical denom-
inators and time horizons that relate to a specific reference
class [12]. For example, out of 100 patients with acute is-
chaemic stroke who receive thrombolytic treatment, it is
likely that 60, 30 and 10 will be functionally independent,
dependent and dead respectively after three months [and
there is a risk of SICH in 2 out of every 100 patients
treated with thrombolysis]; whereas out of 100 patients
not treated with thrombolysis it is likely that 42, 48 and 10
will be functionally independent, dependent and dead re-
spectively after three months – the absolute benefit oftreatment with thrombolysis is 18 more patients out of
100 will be independent three months after a stroke).
Graphical displays provide a further mechanism for
supporting accurate interpretation of probabilistic infor-
mation [76], and there is evidence that graphical options
such as pictograms/graphs are acceptable to patients ir-
respective of differences in health literacy [77]. However,
the optimal form of graphical display is contentious [76]
and we recommend that researchers elicit clinicians' and
patients' views and preferences on a range of characteris-
tics of graphical risk presentations during the develop-
ment process (e.g., format such as bar graphs [clustered
or stacked] and pictograms/graphs to convey natural fre-
quencies [with and without specific treatments, includ-
ing absolute differences], use of colour [being mindful of
red-green colour blindness], and order that information
on outcomes is presented). Nonetheless, no single method
of presenting probabilistic information is likely to be con-
sistent with preferences of all potential users; therefore,
multiple methods of presenting probabilistic information
is recommended [11-13].
We further advocate that researchers should investigate
the potential value of tailoring outcome probabilities to
individual patients [13] for enhancing clinical decision
making based on individual differential effectiveness in
order to aid patients/relatives to understand and consider
trade-offs between the benefits, risks and consequences
associated with available options and hence make a deci-
sion about treatment that is consistent with their prefer-
ences and values [13]. However, a prerequisite for tailoring
outcomes to individual patients is the availability of robust
predictive models that adequately reflect outcomes in rou-
tine practice settings. In the absence of suitable predictive
models, extensive statistical modelling work is warranted
using techniques such as decision analytic modelling [78].
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decision-making in emergency care contexts are likely to
differ from those designed for use in contexts where
there is time for protracted discussions, and where pa-
tients/carers can access support and resources outside
the consultation. In emergency care settings (e.g., treat-
ment decision making about thrombolysis in acute
stroke care) usability testing should be undertaken to es-
tablish the optimal mode, form and information content
of tools for a specific emergency context to enable rapid
use by clinicians and patients/carers. Such tools could be
used in parallel to other procedures across an emergency
care pathway so as to negate/minimise any negative im-
pact on time for decision making and receipt of treat-
ment. In emergency settings, structured decision aids
have been shown to be feasible for eliciting patients’
preferences and values about management and treatment
options [8].
The cultural sensitivity of tools to support patient
understanding and decision making is a further area in
need of research. Simply translating tools into multiple
languages is unlikely to address the influence of cul-
tural variation on patient preferences and values, or
the applicability of tools to support involvement of
patients in decision making with clinicians across
cultural groups [79].
Practice implications
The critical appraisal of tools to support decision making
or patient understanding about thrombolytic treatment
highlights several important implications for implementa-
tion of analogous tools in other clinical contexts. Tools
with limitations across the multiple domains described in
this review are unlikely to be sensitive to the needs of tar-
get users and the complexity of the clinical context. Tools
with low scores on the IPDASi probabilities items check-
list will limit their ability to support patients/carers to
make informed values-based decisions. For example, tools
that present unbalanced synopses of probabilistic informa-
tion on outcome states, without appropriate methods of
supporting health literacy, may cause clinicians and pa-
tients to over- or under-estimate benefits or adverse ef-
fects associated with the available options; for example as
a result of using percentages to convey single event prob-
abilities [61] (e.g., 60% chance of being independent after
a treatment with thrombolysis for acute stroke), relative
risk reduction [75], and framing effects [80].
Consequently, tools with significant limitations will di-
minish their ability to support patient choice, facilitate
self-management of illness, improve patient adherence
to treatment, and enhance communication processes
between clinicians and patients. In the case of decision
aids, such limitations will restrict opportunities for
patients to clarify their personal preferences and valueswith regards to the available options - prerequisites for
informed values-based decisions [13].
Additional issues that are important for effective imple-
mentation of quality tools include training of clinicians to
support patient involvement in healthcare and skills devel-
opment in risk communication, including strategies to sup-
port dissemination and social marketing of quality tools
[10,81,82]. Relevance and quality of information content of
tools may diminish rapidly over time (due to availability of
new data on effectiveness of the options for a specific
health condition, including changes to clinical practice and
information systems that can support delivery of decision
support/risk communication), with a concomitant negative
impact on uptake rates. Resources and appropriate systems
should therefore be in place to periodically assess the rele-
vance of tools and where necessary, update the mode of
delivery, form and information content [81].
Undertaking a definitive randomised controlled trial
(following a positive exploratory trial) as part of a struc-
tured development process has important benefits [9];
however, upon trial completion the relevance and quality
of information content for clinical and patient/relative
benefit could have diminished. This underpinned our de-
cision to omit an item ‘was the tool subjected to a defini-
tive randomised controlled trial?’ from the development
process checklist, and is consistent with the proposal that
tools of sufficient quality may be more appropriately tested
and further refined within the context of 'real time' service
evaluations [10]. There are trade-offs to consider between
the pros and cons of these options for implementation of
tools following a positive exploratory trial in routine prac-
tice settings. A key issue in need of further debate is
whether an equivalent of level of evidence required to
license or implement psychological, pharmacological or
surgical interventions is warranted for implementation of
tools of sufficient quality (underpinned by a structured
development process and pilot tested in clinical settings,
with no apparent risks to safety/adverse effects) to support
patient understanding and decision making about these
types of interventions.
New tools to support patient understanding and
decision making about preference-sensitive healthcare
options/decisions are warranted when none currently
exist. Tool development is a time- and resource-intensive
process, and in cases where numerous tools already exist
for a health condition of interest, an optimal strategy
would be to adapt currently available tools so they fulfil
quality standards [81], informed by a critical evaluation
across the multiple domains described in this review, with
reference to published guidance [6,10-13].
Conclusions
Currently available tools to support decision-making or
patient understanding in the treatment of acute stroke
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In particular, the great majority of tools lacked compre-
hensive development processes; failed to convey informa-
tion on a full range of range of outcome states; and did
not adhere to good practice on presentation of outcome
probabilities. This has implications that go beyond tools
for this clinical setting to other contexts where decision
support and risk presentation is being developed.
The potential impact of tools for supporting decision
making and increasing patient understanding of
preference-sensitive treatment options will be en-
hanced when they are (i) underpinned by an auditable
structured development process that has meaningfully
involved target users throughout the design and testing
process; and (ii) utilised evidence-based methods to
present a balanced synopsis of probabilistic information
on the full range of outcome states, that is understandable
and interpretable by patients with different levels of health
literacy. Issues such as training/skills development for
clinicians and dissemination plans, including strategies to
sustain relevance and quality of information content over
time, are also key elements in the equation for the effect-
ive implementation of tools in clinical settings.
Endnote
a please contact the corresponding author for copies of
these tools.
Additional file
Additional file 1: Electronic search strategy for Medline. (keywords
and MeSH terms).
Abbreviations
ICH: Intracranial haemorrhage; IPDASi: International patient decision aid
standards instrument; rt-PA: Recombinant tissue plasminogen activator;
SICH: Symptomatic intracranial haemorrhage.
Competing interests
LS and MJM have no competing interests to declare. DF, GAF, HR and RGT
have been involved in developing a computerised decision aid for
thrombolytic treatment in acute stroke care. This may be made available for
a cost payable to download the decision aid to cover the costs of technical
maintenance and updating of the information content (predictive equations
and user interface) in accordance with user feedback and availability of new
data on the effectiveness of thrombolysis. GAF’s institution has received
research grants from Boehringer Ingelheim (manufacturer of Alteplase), and
honoraria from Lundbeck for stroke-related activities. GAF has also received
personal remuneration for educational and advisory work from Boehringer
Ingelheim and Lundbeck.
Authors' contributions
RGT, GAF and HR conceived the study. DF conducted the electronic
searches. DF and RGT assessed eligibility of tools for inclusion in the review,
and conducted data extraction and quality appraisal. All authors provided
input to the development of the methods and the drafting process. All
authors read and approved the final manuscript.
Acknowledgements
Thanks to Dr Kerry Joyce, Institute of Health and Society, Newcastle
University, UK for assistance with the literature search and manuscriptpreparation; and the following individuals for assistance with the
international survey: Dr Martin James, British Association of Stroke Physicians;
Professor Jeff Saver, Geffen School of Medicine, UCLA, USA; Professor Richard
Lindley, University of Sydney, Australia; Dr. Antoine Hakim, Ottawa Hospital
Research Institute, Canada.
This report is independent research funded by the National Institute for
Health Research under its Programme Grants for Applied Research scheme
(Development and evaluation of hyperacute services for patients with acute
stroke: RP-PG-0606-1241). The views expressed in this publication are those
of the author(s) and not necessarily those of the NHS, the National Institute
for Health Research or the Department of Health. The NIHR had no role in
study design, data collection, data analysis, data interpretation, or writing of
the manuscript. GAF is supported by an NIHR Senior Investigator award.
Author details
1Institute of Health and Society, Newcastle University, Newcastle Upon Tyne,
UK. 2Institute for Ageing and Health (Stroke Research Group), Newcastle
University, Newcastle Upon Tyne, UK. 3Department of Health Sciences,
University of Leicester, Leicester, UK.
Received: 25 February 2013 Accepted: 6 June 2013
Published: 18 June 2013
References
1. Barry MJ, Edgman-Levitan S: Shared decision making - the pinnacle of
patient-centred care. New Engl J Med 2012, 366:780–781.
2. Charles C, Whelan T, Gafni A: What do we mean by partnership in making
decisions about treatment? Brit Med J 1999, 319:780–782.
3. Sepucha KR, Fowler FJ, Mulley AG: Policy support for patient-centered
care: The need for measurable improvements in decision quality.
Health Aff (Millwood) 2004, Suppl Variation:VAR54–VAR62.
4. Bright TJ, Wong A, Dhurjati R, Bristow E, Bastian L, Coeytaux RR, Samsa G,
Hasselblad V, Williams JW, Musty MD, Wing L, Kendrick AS, Sanders GD,
Lobach D: Effect of clinical decision-support systems: a systematic
review. Ann Intern Med 2012, 157:29–43.
5. Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M, Llewellyn-
Thomas H, Lyddiatt A, Légaré F, Thomson R: Decision aids for people facing
health treatment or screening decisions. Cochrane Database Syst Rev 2011,
Issue 10:Art. No.:CD001431. doi:10.1002/14651858.CD001431.pub3.
6. Coulter A, Ellins J, Swain D, Clarke A, Heron P, Rasul F, Magee H, Sheldon H:
Assessing the quality of information to support people in making decisions
about their health and healthcare. Oxford: Picker Institute Europe; 2006.
7. Edwards A, Elwyn G, Gwyn R: General practice registrar responses to the
use of different risk communication tools in simulated consultations: a
focus group study. Brit Med J 1999, 319:749–752.
8. Flynn D, Pierce M, Hess E, Murad MH, Erwin PJ, Montori V, Thomson RG:
Engaging patients in healthcare decisions in the emergency department
through shared decision making: a systematic review. Acad Emerg Med
2012, 19:959–967.
9. Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P,
Spiegelhalter D, Tyrer P: Framework for design and evaluation of complex
interventions to improve health. Brit Med J 2000, 321:694–696.
10. Elwyn G, Kreuwel I, Durand MA, Sivell S, Joseph-Williams N, Evans R,
Edwards A: How to develop web-based decision support interventions
for patients: A process map. Patient Educ Couns 2011, 82:260–265.
11. Elwyn G, O’Connor A, Stacey D, Volk R, Edwards A, Coulter A, Thomson R,
Barratt A, Barry M, Bernstein S, Butow P, Clarke A, Entwistle V, Feldman-
Stewart D, Holmes-Rovner M, Llewellyn-Thomas H, Moumjid N, Mulley A,
Ruland C, Sepucha K, Sykes A, Whelan T: International Patient Decision
Aids Standards (IPDAS) Collaboration: Developing a quality criteria
framework for patient decision aids: online international Delphi
consensus process. Brit Med J 2006, 333:417–421.
12. Elwyn G, O’Connor AM, Bennett C, Newcombe RG, Politi M, Durand MA, Drake
E, Joseph-Williams N, Khangura S, Saarimaki A, Sivell S, Stiel M, Bernstein SJ, Col
N, Coulter A, Eden K, Härter M, Rovner MH, Moumjid N, Stacey D, Thomson R,
Whelan T, van der Weijden T, Edwards A: Assessing the quality of decision
support technologies using the international patient decision aid standards
instrument (IPDASi). PLoS One 2009, 4:e4705.
13. International Patient Decision Aid Standards (IPDAS) Collaboration: 2012
Update of the IPDAS Collaboration Background Document. http://ipdas.ohri.
ca/resources.html.
Flynn et al. BMC Health Services Research 2013, 13:225 Page 12 of 13
http://www.biomedcentral.com/1472-6963/13/22514. Lees KR, Bluhmki E, Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M,
Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W, ECASS,
ATLANTIS, NINDS and EPITHET rt-PA Study Group: Time to treatment with
intravenous alteplase and outcome in stroke: an updated pooled analysis of
ECASS, ATLANTIS, NINDS and EPITHET trials. Lancet 2010, 375:1695–1703.
15. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V,
Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N,
Toni D: ECASS Investigators: Thrombolysis with alteplase 3 to 4.5 hours
after acute ischemic stroke. New Engl J Med 2008, 359:1317–1329.
16. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, Hennerici MG,
Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G:
SITS-MOST investigators: Thrombolysis with alteplase for acute ischaemic
stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring
Study (SITS-MOST): an observational study. Lancet 2007, 369:275–282.
17. Lansberg MG, Albers GW, Wijman CA: Symptomatic intracerebral
hemorrhage following thrombolytic therapy for acute ischemic stroke: a
review of the risk factors. Cerebrovasc Dis 2007, 24:1–10.
18. The Third International Stroke Trial (IST-3) collaborative group: The benefits
and harms of intravenous thrombolysis with recombinant tissue
plasminogen activator within 6 h of acute ischaemic stroke (the third
international stroke trial [IST-3]): a randomised controlled trial. Lancet
2012, 379:2352–2363.
19. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL,
Cohen G: Recombinant tissue plasminogen activator for acute ischaemic
stroke: an updated systematic review and meta-analysis. Lancet 2012,
379:2364–2372.
20. Ciccone A: Consent to thrombolysis in acute ischaemic stroke: from trial
to practice. Lancet Neurol 2003, 2:375–378.
21. Rosenbaum JR, Bravata DM, Concato J, Brass LM, Kim N, Fried TR: Informed
consent for thrombolytic therapy for patients with acute ischemic stroke
treated in routine clinical practice. Stroke 2004, 35:e353–e355.
22. Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA: Patient preferences
for stroke outcomes. Stroke 1994, 25:1721–1725.
23. Murtagh MJ, Burges Watson DL, Jenkings KN, Lie MLS, Mackintosh JE, Ford GA,
Thomson RG: Situationally-sensitive knowledge translation and relational
decision making in hyperacute stroke: a qualitative study. PLoS One 2012,
7(6):e37066.
24. Intercollegiate Stroke Working Party: Stroke Improvement National Audit
Programme (SINAP): Public Comprehensive Report 2012. http://www.rcplondon.
ac.uk/sites/default/files/sinap-comprehensive-public-report-2012.pdf.
25. Lecouturier J, Murtagh MJ, Thomson RG, Ford GA, White M, Eccles M,
Rodgers H: Response to symptoms of stroke in the UK: a systematic
review. BMC Health Serv Res 2010, 10:157.
26. National Audit Office: Progress in improving stroke care: a good practice
guide. London: National Audit Office; 2010.
27. Kwan J, Hand P, Sandercock P: A systematic review of barriers to delivery
of thrombolysis for acute stroke. Age Ageing 2004, 33:116–121.
28. Brown DL, Barsan WG, Lisabeth LD, Gallery ME, Morgenstern LB: Survey of
emergency physicians about recombinant tissue plasminogen activator
for acute ischemic stroke. Ann Emerg Med 2005, 46:56–60.
29. Dirks M, Niessen LW, Koudstaal PJ, Franke CL, van Oostenbrugge RJ, Dippel
DW: Intravenous thrombolysis in acute ischaemic stroke: from trial
exclusion criteria to clinical contraindications. An international Delphi
study. J Neurol Neurosurg Psychiatry 2007, 78:685–689.
30. Wardlaw JM, Murray V, Berge E, del Zoppo GJ: Thrombolysis for acute
ischaemic stroke. Cochrane Database Syst Rev 2009, 4, CD000213.
31. Bonita R, Beaglehole R: Modification of Rankin Scale: Recovery of motor
function after stroke. Stroke 1988, 19:1497–1500.
32. Gunning R: The technique of clear writing. New York, NY: McGraw-Hill; 1952.
33. Bond S: Gunning Fog Index. http://gunning-fog-index.com/index.html.
34. Knapp P, Wanklyn P, Raynor DK, Waxman R: Developing and testing a
patient information booklet for thrombolysis used in acute stroke.
Int J Pharm Pract 2010, 18:362–369.
35. American Academy of Neurology: American College of Emergency Physicians,
and American Heart Association/American Stroke Association: Tissue
plasminogen activator (tPA): what you should know. http://www.heart.org/
idc/groups/ahaecc-public/@wcm/@hcm/@gwtg/documents/downloadable/
ucm_431151.pdf.
36. Patient UK: Thrombolytic treatment of acute ischaemic stroke. [the version of
this tool that was critically analysed in this paper is no longer available via
the weba]37. Stockport NHS Foundation Trust: Stroke thrombolysis (clot dissolving drugs):
an information leaflet. [the version of this tool that was critically analysed in
this paper is no longer available via the weba]
38. University Hospitals Bristol NHS Foundation Trust: Acute stroke thrombolysis.
[the version of this tool that was critically analysed in this paper is no
longer available via the weba]
39. Genentech: After a stroke starts: what you need to know about clot-busting therapy.
http://www.icahn.org/files/Stroke_Library_/Tools/activase_patientbroch.pdf.
40. Thunder Bay Regional Health Sciences Centre: Information about tPA.
http://www.tbrhsc.net/clinical_partners/regional_stroke_program/
TPA_information.asp.
41. Chest, Heart and Stroke Scotland: Thrombolysis treatment after stroke. [the
version of this tool that was critically analysed in this paper is no longer
available via the weba]
42. Ottawa Hospital: Information for patients and families about tPA (Tissue
Plasminogen) for stroke. http://www.ottawaneurology.ca/docs/Stroke_Pack/
stroke0015.pdf.
43. Massachusetts General Hospital Stroke Service: Patient information sheet.
http://www2.massgeneral.org/stopstroke/pdfs/Patient%20Information%
20Sheet%20(IV%20tPA%20in%20the%203-4.5hrs).pdf.
44. South Tyneside NHS Foundation Trust: Stroke thrombolysis - information
sheet. http://www.easyhealth.org.uk/sites/default/files/Stroke%
20Thrombolysis%20%E2%80%93%20Information%20Sheet.pdf.
45. Gloucestershire Hospitals NHS Foundation Trust: Stroke thrombolysis
information for patients and relatives. http://www.strokeunitglos.nhs.uk/
strokeunitgl282427.html.
46. NHS Wales: Patient and carer information leaflet: thrombolysis in stroke.
[the version of this tool that was critically analysed in this paper is no
longer available via the weba]
47. Saint Alphonsus Health System Outreach Program: t-PA information sheet. http://
www.saintalphonsus.org/documents/StrokeThrombolyticsConsentForm.pdf.
48. NHS Fife: Patient information sheet for thrombolysis. http://www.sctt.scot.nhs.
uk/wp-content/uploads/2012/11/FifeThrombolysisprotocolJan10v1.pdf.
49. Royal United Hospital Bath NHS Trust: Information for patients about
thrombolysis (clot dissolving drugs) for stroke. [the version of this tool that
was critically analysed in this paper is no longer available via the weba]
50. University of North Staffordshire NHS Trust: Thrombolysis (treatment with a
clot dissolving drug - alteplase) for acute stroke. www.stroke-in-stoke.info/
acutestrokefiles/thrombolysispathway.doc.
51. American Academy of Emergency Medicine: tPA for stroke—potential benefit,
risk and alternatives. http://www.aaem.org/UserFiles/file/tpaedtool-AAEM.pdf.
52. Gadhia J, Starkman S, Ovbiagele B, Ali L, Liebeskind D, Saver JL: Assessment
and improvement of figures to visually convey benefit and risk of stroke
thrombolysis. Stroke 2010, 41:300–306.
53. Genentech: Hypothetical representation of 16 patients treated with Activase
(t-PA) vs 16 patients treated with placebo is based on NINDS results at 3 months.
[the version of this tool that was critically analysed in this paper is no
longer available via the weba]
54. NHS Lothian: Clot-busting treatment for acute stroke: patient information.
[http://www.lothianstrokemcn.scot.nhs.uk/network_groups/documents/
ThrombolysisPatientInfo_WW.pdf]
55. NHS Lothian: Clot-busting treatment for acute stroke: patient information. http://
www.strokeadvancingmodules.org/resources/ThrombolysisPatientInfo.pdf.
56. Shapiro J, Bessette M, Levine SR, Baumlin K: HandiStroke: a handheld tool
for the emergent evaluation of acute stroke patients. Acad Emerg Med
2003, 10:1325–1328.
57. Kent DM, Selker HP, Ruthazer R, Bluhmki E, Hacke W: The Stroke-Thrombolytic
Predictive Instrument: a predictive instrument for intravenous thrombolysis
in acute ischemic stroke. Stroke 2006, 37:2957–2962.
58. Cunningham VL: The outcome wheel: a potential tool for shared
decision-making in ischemic stroke thrombolysis. CJEM 2008, 10:545–551.
59. Stroke Northumbria: Stroke Thrombolysis Pathway 2009: Information to give
to patients/relatives before administration of Alteplase. [the version of this
tool that was critically analysed in this paper is no longer available via the weba]
60. Thomson R, Edwards A, Grey J: Risk communication in the clinical
consultation. Clin Med 2005, 5:465–469.
61. Gigerenzer G, Galesic M: Why do single event probabilities confuse
patients? Statements of frequency are better for communicating risk. Brit
Med J 2012, 344:e245.
62. Rothwell PM: External validity of randomised controlled trials: “To whom
do the results of this trial apply?”. Lancet 2005, 365:82–93.
Flynn et al. BMC Health Services Research 2013, 13:225 Page 13 of 13
http://www.biomedcentral.com/1472-6963/13/22563. Cleveland WS, McGill R: Graphical perception and graphical methods for
analyzing scientific data. Science 1985, 229:828–833.
64. Doak CC, Doak LG, Root JH: Teaching patients with low literacy skills.
Philadelphia, PA: Lippincott-Raven; 1996.
65. Weiss BD, Coyne C: Communicating with patients who cannot read.
New Engl J Med 1997, 337:272–274.
66. Coulter A, Entwistle V, Gilbert D: Informing patients: an assessment of the
quality of patient information materials. London: King's Fund; 1998.
67. Charvet-Berard AI, Chopard P, Perneger TV: Measuring quality of patient
information documents with an expanded EQIP scale. Patient Educ Couns
2008, 70:407–411.
68. Durand MA, Boivin J, Elwyn G: A review of decision support technologies
for amniocentesis. Hum Reprod Update 2008, 14:659–668.
69. Durand MA, Stiel M, Boivin J, Elwyn G: Where is the theory?: Evaluating
the theoretical frameworks described in decision support technologies.
Patient Educ Couns 2008, 71:125–135.
70. Hazelton G, Al-Khatib SM, Fonarow GC, Thomas KL, Hayes D, Sanders GD,
Campbell SM, Yancy C, Peterson ED, Sears S: Assessment of the quality of
existing patient educational tools focused on sudden cardiac arrest: a
systematic evaluation by the Sudden Cardiac Arrest Thought Leadership
Alliance. Patient Prefer Adherence 2013, 7:361–368.
71. Thomson R, Robinson A, Greenaway J, Lowe P: DARTS Team: Development
and description of a decision analysis based decision support tool for
stroke prevention in atrial fibrillation. Qual Saf Health Care 2002, 11:25–31.
72. Hess EP, Knoedler MA, Shah ND, Kline JA, Breslin M, Branda ME, Pencille LJ,
Asplin BR, Nestler DM, Sadosty AT, Stiell IG, Ting HH, Montori VM: The chest
pain choice decision aid: A randomized trial. Circ Cardiovasc Qual
Outcomes 2012, 5:251–259.
73. Sivell S, Marsh W, Edwards A, Manstead AS, Clements A, Elwyn G: Theory-
based design and field-testing of an intervention to support women
choosing surgery for breast cancer: BresDex. Patient Educ Couns 2012,
86:179–188.
74. Gigerenzer G: Reckoning with risk. London: Penguin; 2002.
75. Akl EA, Oxman AD, Herrin J, Vist GE, Terrenato I, Sperati F, Costiniuk C, Blank
D, Schünemann H: Using alternative statistical formats for presenting
risks and risk reductions. Cochrane Database Syst Rev 2011, Issue 3: Art.
No.: CD006776. doi:10.1002/14651858.CD006776.pub2.
76. Spiegelhalter D, Pearson M, Short I: Visualizing uncertainty about the
future. Science 2011, 333:1393–1400.
77. Hawley ST, Zikmund-Fisher BJ, Ubel PA, Jancovic A, Lucas T, Fagerlin A: The
impact of the format of graphical presentation on health-related
knowledge and treatment choices. Patient Educ Couns 2008, 73:448–455.
78. Philips Z, Ginnelly L, Sculphe M, Claxton K, Golder S, Riemsma R, Woolacott
N, Glanville J: Review of guidelines for good practice in decision-analytic
modelling in health technology assessment. Health Technol Assess 2004,
8:number 36. http://www.hta.ac.uk/execsumm/summ836.htm.
79. Charles C, Gafni A, Whelan T, O'Brien MA: Cultural influences on the
physician-patient encounter: the case of shared treatment decision-
making. Patient Educ Couns 2006, 63:262–267.
80. Tversky A, Kahneman D: The framing of decisions and the psychology of
choice. Science 1981, 211:453–458.
81. Elwyn G, Laitner S, Coulter A, Walker E, Watson P, Thomson R:
Implementing shared decision making in the NHS. Brit Med J 2010,
341:971–973.
82. Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P,
Cording E, Tomson D, Dodd C, Rollnick S, Edwards S, Barry M: Shared
decision making: a model for clinical practice. J Gen Int Med 2012,
27:1361–1367.
doi:10.1186/1472-6963-13-225
Cite this article as: Flynn et al.: A review of decision support, risk
communication and patient information tools for thrombolytic
treatment in acute stroke: lessons for tool developers. BMC Health
Services Research 2013 13:225.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
